U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H19FN4O4.ClH
Molecular Weight 434.8493
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FINAFLOXACIN HYDROCHLORIDE

SMILES

C1CC1n2cc(c(=O)c3cc(c(c(C#N)c32)N4C[C@@]5([H])[C@]([H])(C4)OCCN5)F)C(=O)O.Cl

InChI

InChIKey=CQMSQUOHWYYEKM-MOGJOVFKSA-N
InChI=1S/C20H19FN4O4.ClH/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15;/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28);1H/t15-,16-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C20H19FN4O4
Molecular Weight 398.3884
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=25808831; http://www.ncbi.nlm.nih.gov/pubmed/26068714;

Finafloxacin is a fluoroquinolone antimicrobial agent that exhibits optimum efficacy in slightly acidic environments and is a highly potent eradicator of Helicobacter pylori. Being developed to treat serious bacterial infections associated with an acidic environment, including urinary tract infections and Helicobacter pylori infections finafloxacin is approved for treatment of acute otitis externa (swimmer’s ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. XTORO (finafloxacin otic suspension), 0.3% is supplied as a sterile, preserved, aqueous suspension. Finafloxacin is a drug with a favorable safety profile.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: 950199.0
Gene Symbol: gyrA
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
XTORO

Approved Use

Indicated for the treatment of acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus in patients age 1 year and older.

Launch Date

1.41877445E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.67 mg/L
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.76 mg/L
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
8.68 mg/L
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
8.84 mg/L
600 mg single, intravenous
dose: 600 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
9.15 mg/L
600 mg 1 times / day multiple, intravenous
dose: 600 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8.95 mg/L
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.69 mg/L
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
11.5 mg/L
800 mg single, intravenous
dose: 800 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
37.8 mg/L
800 mg 1 times / day multiple, intravenous
dose: 800 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.5 mg/L
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
17.1 mg/L
1000 mg single, intravenous
dose: 1000 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
18.1 mg/L
1000 mg 1 times / day multiple, intravenous
dose: 1000 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.96 mg/L
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4.15 mg/L
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.44 mg/L
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6 mg/L
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
8 mg/L
600 mg single, intravenous
dose: 600 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
11.1 mg/L
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
13.3 mg/L
800 mg single, intravenous
dose: 800 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.9 mg/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
20.2 mg/L
1000 mg single, intravenous
dose: 1000 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.56 mg/L
200 mg single, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
18.7 mg × h/L
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
19.2 mg × h/L
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
20.8 mg × h/L
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
21.8 mg × h/L
600 mg single, intravenous
dose: 600 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
24.3 mg × h/L
600 mg 1 times / day multiple, intravenous
dose: 600 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
26.1 mg × h/L
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.76 mg × h/L
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
32 mg × h/L
800 mg single, intravenous
dose: 800 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
35.4 mg × h/L
800 mg 1 times / day multiple, intravenous
dose: 800 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.01 mg × h/L
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
49.8 mg × h/L
1000 mg single, intravenous
dose: 1000 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
64.1 mg × h/L
1000 mg 1 times / day multiple, intravenous
dose: 1000 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8.75 mg × h/L
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9.09 mg × h/L
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.26 mg × h/L
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
14.7 mg × h/L
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
21.8 mg × h/L
600 mg single, intravenous
dose: 600 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
29.2 mg × h/L
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
31.7 mg × h/L
800 mg single, intravenous
dose: 800 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.08 mg × h/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
46.9 mg × h/L
1000 mg single, intravenous
dose: 1000 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6.85 mg × h/L
200 mg single, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.8 h
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.9 h
600 mg 1 times / day multiple, intravenous
dose: 600 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
14 h
800 mg 1 times / day multiple, oral
dose: 800 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
15 h
800 mg 1 times / day multiple, intravenous
dose: 800 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.3 h
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
16.9 h
1000 mg 1 times / day multiple, intravenous
dose: 1000 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6.5 h
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.8 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
12.1 h
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
11.7 h
600 mg single, intravenous
dose: 600 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
10.5 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
15.3 h
800 mg single, intravenous
dose: 800 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.06 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
17.1 h
1000 mg single, intravenous
dose: 1000 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10.6 h
200 mg single, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
FINAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.3 % 2 times / day multiple, topical
Recommended
Dose: 0.3 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.3 %, 2 times / day
Sources: Page: p.18, p.21
unhealthy, 11 months - 84 years
n = 618
Health Status: unhealthy
Condition: Acute otitis externa
Age Group: 11 months - 84 years
Sex: M+F
Population Size: 618
Sources: Page: p.18, p.21
Other AEs: Ear pruritus, Nausea...
Other AEs:
Ear pruritus (1.3%)
Nausea (1.1%)
Sources: Page: p.18, p.21
1000 mg 1 times / day multiple, intravenous
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 1000 mg, 1 times / day
Sources: Page: p.4
healthy, 53 (5.9)
n = 8
Health Status: healthy
Age Group: 53 (5.9)
Sex: M+F
Population Size: 8
Sources: Page: p.4
800 mg 1 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.4390
healthy
n = 6
Health Status: healthy
Sex: M
Population Size: 6
Sources: Page: p.4390
0.3 % 2 times / day multiple, topical
Recommended
Dose: 0.3 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.3 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute otitis externa
Sources: Page: p.1
Other AEs: Overgrowth of nonsusceptible organisms, Allergic reaction...
Other AEs:
Overgrowth of nonsusceptible organisms
Allergic reaction
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Nausea 1.1%
0.3 % 2 times / day multiple, topical
Recommended
Dose: 0.3 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.3 %, 2 times / day
Sources: Page: p.18, p.21
unhealthy, 11 months - 84 years
n = 618
Health Status: unhealthy
Condition: Acute otitis externa
Age Group: 11 months - 84 years
Sex: M+F
Population Size: 618
Sources: Page: p.18, p.21
Ear pruritus 1.3%
0.3 % 2 times / day multiple, topical
Recommended
Dose: 0.3 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.3 %, 2 times / day
Sources: Page: p.18, p.21
unhealthy, 11 months - 84 years
n = 618
Health Status: unhealthy
Condition: Acute otitis externa
Age Group: 11 months - 84 years
Sex: M+F
Population Size: 618
Sources: Page: p.18, p.21
Allergic reaction
0.3 % 2 times / day multiple, topical
Recommended
Dose: 0.3 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.3 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute otitis externa
Sources: Page: p.1
Overgrowth of nonsusceptible organisms
0.3 % 2 times / day multiple, topical
Recommended
Dose: 0.3 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.3 %, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute otitis externa
Sources: Page: p.1
PubMed

PubMed

TitleDatePubMed
In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
2007 Mar
Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose.
2011
Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes.
2011 Dec
Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila.
2011 Jul
In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions.
2011 Sep
Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers.
2011 Sep
Activity of the investigational fluoroquinolone finafloxacin and seven other antimicrobial agents against 114 obligately anaerobic bacteria.
2014 Nov
Finafloxacin: first global approval.
2015 Apr
Patents

Sample Use Guides

Instill four drops into the affected ear(s) twice daily for seven days. For patients requiring use of an otowick, the initial dose can be doubled (to 8 drops), followed by 4 drops instilled into the affected ear twice daily for seven days.
Route of Administration: Otic (auricular)
In Vitro Use Guide
At low pH=5,8 and in range of concentrations: 0,006 - 0,25 mg/L finafloxacin showed the highest activity among all tested fluoroquinolones against S. aureus, including the methicillin-resistant S. aureus (MRSA) pairs and coagulase-negative staphylococcal (CoNS) tested
Substance Class Chemical
Created
by admin
on Sat Jun 26 14:48:40 UTC 2021
Edited
by admin
on Sat Jun 26 14:48:40 UTC 2021
Record UNII
2G22PNZ052
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FINAFLOXACIN HYDROCHLORIDE
MI  
Common Name English
BAY-353377
Code English
3-QUINOLINECARBOXYLIC ACID, 8-CYANO-1-CYCLOPROPYL-6-FLUORO-7-((4AS,7AS)-HEXAHYDROPYRROLO(3,4-B)-1,4-OXAZIN-6(2H)-YL)-1,4-DIHYDRO-4-OXO-, MONOHYDROCHLORIDE
Systematic Name English
BAY 35-3377
Code English
BAY35-3377
Code English
FINAFLOXACIN HYDROCHLORIDE [MI]
Common Name English
BAY-35-3377
Code English
Code System Code Type Description
FDA UNII
2G22PNZ052
Created by admin on Sat Jun 26 14:48:41 UTC 2021 , Edited by admin on Sat Jun 26 14:48:41 UTC 2021
PRIMARY
DRUG BANK
DBSALT001107
Created by admin on Sat Jun 26 14:48:41 UTC 2021 , Edited by admin on Sat Jun 26 14:48:41 UTC 2021
PRIMARY
PUBCHEM
11662028
Created by admin on Sat Jun 26 14:48:41 UTC 2021 , Edited by admin on Sat Jun 26 14:48:41 UTC 2021
PRIMARY
MERCK INDEX
M5382
Created by admin on Sat Jun 26 14:48:41 UTC 2021 , Edited by admin on Sat Jun 26 14:48:41 UTC 2021
PRIMARY Merck Index
CAS
209342-41-6
Created by admin on Sat Jun 26 14:48:41 UTC 2021 , Edited by admin on Sat Jun 26 14:48:41 UTC 2021
PRIMARY
EPA CompTox
209342-41-6
Created by admin on Sat Jun 26 14:48:41 UTC 2021 , Edited by admin on Sat Jun 26 14:48:41 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY